These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27364124)

  • 41. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
    Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
    Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo.
    Cocco C; Di Carlo E; Zupo S; Canale S; Zorzoli A; Ribatti D; Morandi F; Ognio E; Airoldi I
    Leukemia; 2012 Jun; 26(6):1365-74. PubMed ID: 22193967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy.
    Wu X; Ban C; Deng W; Bao X; Tang N; Wu Y; Deng Z; Xiong J; Zhao Q
    Mol Cancer; 2024 Jul; 23(1):144. PubMed ID: 39004737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
    Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
    Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancing effects of indirubin on the arsenic disulfide-induced apoptosis of human diffuse large B-cell lymphoma cells.
    Wang L; Li X; Liu X; Lu K; Chen NA; Li P; Lv X; Wang X
    Oncol Lett; 2015 Apr; 9(4):1940-1946. PubMed ID: 25789073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
    Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
    Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Establishment and characterization of a nude mice model of human diffuse large B-cell lymphoma].
    Yu BH; Zhou XY; Zhang TC; Zhang TM; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):246-50. PubMed ID: 21615998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
    Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
    Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mda-7/IL-24 enhances sensitivity of B cell lymphoma to chemotherapy drugs.
    Ma M; Zhao L; Sun G; Zhang C; Liu L; Du Y; Yang X; Shan B
    Oncol Rep; 2016 May; 35(5):3122-30. PubMed ID: 26883473
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
    Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
    Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
    Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
    Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
    Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
    Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
    Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1.
    Chang G; Zheng J; Xiao W; Chang S; Wei Q; Wu H; Tao Y; Yang G; Xie B; Lan X; Wang Y; Yu D; Hu L; Xie Y; Bu W; Kong Y; Dai B; Hou J; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):399-407. PubMed ID: 29534146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metadherin interference inhibits proliferation and enhances chemo-sensitivity to doxorubicin in diffuse large B cell lymphoma.
    Li PP; Feng LL; Chen N; Lu K; Meng XH; Ge XL; Lv X; Wang X
    Int J Clin Exp Med; 2014; 7(8):2081-6. PubMed ID: 25232390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway.
    Cha Z; Qian G; Zang Y; Gu H; Huang Y; Zhu L; Li J; Liu Y; Tu X; Song H; Qian B
    Exp Cell Res; 2017 Jan; 350(1):154-160. PubMed ID: 27888017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.